Cantor Fitzgerald initiates Verastem (VSTM) at Buy with a $22 price target noting the company's...

|About: Verastem (VSTM)|By:, SA News Editor

Cantor Fitzgerald initiates Verastem (VSTM) at Buy with a $22 price target noting the company's "scientific and executive founders are a virtual panoply of who's who in cancer stem cell research." Furthermore, analyst Mara Goldstein says the company has a "compelling mix" of other catalysts and VS-6063 (previous) may have applications outside of mesothelioma.